Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Efficacy and toxicity of pembrolizumab in addition to neoadjuvant platinum-based chemotherapy (NAPC) in triple-negative breast cancer (TNBC) patients with and without germline BRCA mutations (gBRCAmut ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...